Prevalence of anal fistula in the United Kingdom.
Anal fistula
Comorbidities
Crohn’s disease
Europe
Prevalence
United Kingdom
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
26 Jul 2019
26 Jul 2019
Historique:
received:
25
02
2019
revised:
08
05
2019
accepted:
23
05
2019
entrez:
17
8
2019
pubmed:
17
8
2019
medline:
17
8
2019
Statut:
ppublish
Résumé
Anal fistula is a pathological connection between the anal canal and perianal skin, which most commonly develops from an infected anal crypt. While the majority of anal fistulas are idiopathic, they are also associated with Crohn's disease (CD) and other inflammatory conditions. The prevalence of anal fistula is estimated to be 1-2 per 10000 patients, but population-based studies on anal fistula epidemiology are limited and outdated. To assess the prevalence of anal fistula and relevant comorbidities, with and without CD in the United Kingdom and Europe. A retrospective population-representative observational cohort study was performed in The Health Improvement Network (THIN), a United Kingdom primary care database. Mid-year point prevalence of anal fistula was calculated on the first of July for each year between 2014 and 2017. Estimates were calculated for anal fistula overall and by CD status and standardized to the United Kingdom and European population. Prevalence of relevant comorbidities including lymphogranuloma venereum, hidradenitis suppurativa, anal presentation of sexually transmitted diseases, diabetes mellitus, and radiation in the pelvic area was reported. The United Kingdom-standardized overall point prevalence of anal fistula was 1.80 (95%CI: 1.65-1.94) per 10000 patients in 2017, while the Europe standardized estimate was 1.83 (95%CI: 1.68-1.98) per 10000 patients. Both these standardized point prevalence estimates ranged from 1.89 to 2.36 between 2014-2016. The United Kingdom-standardized point prevalence of anal fistula without CD was 1.35 (95%CI: 1.23-1.48) per 10000 patients, while the Europe-standardized estimate was 1.39 (95%CI: 1.26-1.52) per 10000 patients. In contrast, the standardized point prevalence estimate of anal fistula with CD was lower for both United Kingdom and Europe (0.44; 95%CI United Kingdom: 0.37-0.52, 95%CI Europe: 0.37-0.51) per 10000 patients in 2017. In 2017, 19% of anal fistula patients without CD and 13% of anal fistula patients with CD had at least one relevant comorbidity. These results show that anal fistulas are infrequent in the general population. 24.5% of prevalent anal fistulas are associated with CD, but other potentially etiological comorbidities are rare. This real-world evidence study estimated the United Kingdom-standardized prevalence of anal fistula was 1.80 per 10000 patients in 2017. Approximately 25% of cases may be associated with CD, while other comorbidities are rare.
Sections du résumé
BACKGROUND
BACKGROUND
Anal fistula is a pathological connection between the anal canal and perianal skin, which most commonly develops from an infected anal crypt. While the majority of anal fistulas are idiopathic, they are also associated with Crohn's disease (CD) and other inflammatory conditions. The prevalence of anal fistula is estimated to be 1-2 per 10000 patients, but population-based studies on anal fistula epidemiology are limited and outdated.
AIM
OBJECTIVE
To assess the prevalence of anal fistula and relevant comorbidities, with and without CD in the United Kingdom and Europe.
METHODS
METHODS
A retrospective population-representative observational cohort study was performed in The Health Improvement Network (THIN), a United Kingdom primary care database. Mid-year point prevalence of anal fistula was calculated on the first of July for each year between 2014 and 2017. Estimates were calculated for anal fistula overall and by CD status and standardized to the United Kingdom and European population. Prevalence of relevant comorbidities including lymphogranuloma venereum, hidradenitis suppurativa, anal presentation of sexually transmitted diseases, diabetes mellitus, and radiation in the pelvic area was reported.
RESULTS
RESULTS
The United Kingdom-standardized overall point prevalence of anal fistula was 1.80 (95%CI: 1.65-1.94) per 10000 patients in 2017, while the Europe standardized estimate was 1.83 (95%CI: 1.68-1.98) per 10000 patients. Both these standardized point prevalence estimates ranged from 1.89 to 2.36 between 2014-2016. The United Kingdom-standardized point prevalence of anal fistula without CD was 1.35 (95%CI: 1.23-1.48) per 10000 patients, while the Europe-standardized estimate was 1.39 (95%CI: 1.26-1.52) per 10000 patients. In contrast, the standardized point prevalence estimate of anal fistula with CD was lower for both United Kingdom and Europe (0.44; 95%CI United Kingdom: 0.37-0.52, 95%CI Europe: 0.37-0.51) per 10000 patients in 2017. In 2017, 19% of anal fistula patients without CD and 13% of anal fistula patients with CD had at least one relevant comorbidity. These results show that anal fistulas are infrequent in the general population. 24.5% of prevalent anal fistulas are associated with CD, but other potentially etiological comorbidities are rare.
CONCLUSION
CONCLUSIONS
This real-world evidence study estimated the United Kingdom-standardized prevalence of anal fistula was 1.80 per 10000 patients in 2017. Approximately 25% of cases may be associated with CD, while other comorbidities are rare.
Identifiants
pubmed: 31417925
doi: 10.12998/wjcc.v7.i14.1795
pmc: PMC6692258
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1795-1804Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Références
Gastroenterology. 2002 Apr;122(4):875-80
pubmed: 11910338
Aliment Pharmacol Ther. 2003 May 1;17(9):1145-51
pubmed: 12752351
Br Med J. 1961 Feb 18;1(5224):463-9
pubmed: 13732880
Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:151A-152A
pubmed: 1498789
J S Afr Vet Assoc. 1992 Jun;63(2):81-2
pubmed: 1501216
BMJ. 1992 Jun 6;304(6840):1511
pubmed: 1611392
Afr Health Sci. 2005 Dec;5(4):345-7
pubmed: 16615850
Clin Gastroenterol Hepatol. 2006 Sep;4(9):1130-4
pubmed: 16905369
Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):393-401
pubmed: 17066486
Int J Colorectal Dis. 2007 Dec;22(12):1459-62
pubmed: 17554546
J Epidemiol Community Health. 2009 Apr;63(4):332-6
pubmed: 19240084
Am J Cardiol. 1991 Oct 1;68(9):843-7
pubmed: 1927941
Colorectal Dis. 2010 Sep;12(9):921-6
pubmed: 19508528
Best Pract Res Clin Gastroenterol. 2009;23(4):575-92
pubmed: 19647691
J Crohns Colitis. 2010 Feb;4(1):63-101
pubmed: 21122490
World J Gastroenterol. 2011 Jul 28;17(28):3292-6
pubmed: 21876616
Pharmacoepidemiol Drug Saf. 2011 Nov;20(11):1138-49
pubmed: 22020900
Clin Colon Rectal Surg. 2011 Mar;24(1):14-21
pubmed: 22379401
Chest. 1990 Mar;97(3):566-71
pubmed: 2306959
BMJ. 1990 Apr 28;300(6732):1092
pubmed: 2344534
Tech Coloproctol. 2014 Jul;18(7):635-9
pubmed: 24452294
Inflamm Bowel Dis. 2014 Nov;20(11):2022-8
pubmed: 25159455
Ann Gastroenterol. 2014;27(4):320-330
pubmed: 25331917
Colorectal Dis. 2015 Dec;17(12):1041-3
pubmed: 26547817
Fortschr Med. 1989 Jul 30;107(22):485-8
pubmed: 2676800
J Infect Dis. 1989 Oct;160(4):662-8
pubmed: 2677162
Minerva Gastroenterol Dietol. 2017 Mar;63(1):44-49
pubmed: 27768009
Cir Esp. 2016 Dec;94(10):588-594
pubmed: 27771095
Dis Colon Rectum. 2016 Dec;59(12):1117-1133
pubmed: 27824697
Biochemistry. 1988 Feb 9;27(3):1058-66
pubmed: 2835075
Inflamm Bowel Dis. 2019 Apr 09;:null
pubmed: 31216573
Dis Colon Rectum. 1988 Apr;31(4):268-72
pubmed: 3359895
Gastroenterology. 1979 Oct;77(4 Pt 2):914-20
pubmed: 467943
Gut. 1973 Nov;14(11):865-69
pubmed: 4761606
Dis Colon Rectum. 1979 Nov-Dec;22(8):566-8
pubmed: 527452
Ann Chir Gynaecol. 1984;73(4):219-24
pubmed: 6508203
Gut. 1980 Jun;21(6):525-7
pubmed: 7429313
Dis Colon Rectum. 1995 Apr;38(4):389-92
pubmed: 7720446
J Chir (Paris). 1997 Nov;134(5-6):243-47
pubmed: 9772981